New approach aims to make tough lung cancer treatment more tolerable
NCT ID NCT07469488
Summary
This study is testing whether a comprehensive prevention plan can help Chinese patients with advanced lung cancer better tolerate treatment with the drug amivantamab. The plan aims to reduce common side effects like skin rash, infusion reactions, and blood clots. Researchers will track 122 patients' quality of life, side effects, and how well the cancer responds over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.